DK1288227T3 - Co-activators of nuclear receptors - Google Patents

Co-activators of nuclear receptors

Info

Publication number
DK1288227T3
DK1288227T3 DK02015042T DK02015042T DK1288227T3 DK 1288227 T3 DK1288227 T3 DK 1288227T3 DK 02015042 T DK02015042 T DK 02015042T DK 02015042 T DK02015042 T DK 02015042T DK 1288227 T3 DK1288227 T3 DK 1288227T3
Authority
DK
Denmark
Prior art keywords
nucleic acid
cell
seq
substances
test system
Prior art date
Application number
DK02015042T
Other languages
Danish (da)
Inventor
Siegmund Wolf
Maik Obendorf
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Application granted granted Critical
Publication of DK1288227T3 publication Critical patent/DK1288227T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

A nucleic acid (I): (a) encoding a polypeptide of Seq. ID No. 2 (2055 amino acids, given in the specification); (b) of Seq. ID No. 1 (6995 base pairs, given in the specification); (c) that hybridizes with one of (a) and/or (b) under stringent conditions; or (d) comprising one of (a)-(c) with degeneration of the genetic code appropriate nucleotide sequence, is new. Independent claims are also included for: (1) a polypeptide encoded by the nucleic acid (I); (2) a vector represented in Seq. ID No. 2, that contains at least one copy of (I); (3) a cell transfected with a nucleic acid (I) or with the vector (2); (4) use of a cell (3) to express (I); (5) use of (1) or a part of it for the production of antibodies; (6) an antibody against (1); (7) use of (6) for the detection of (1); (8) use of a probe with nucleic acid sequences which are complementary to the nucleic acid sequence, which encode (1), for the production of a reagent for proving the presence of mRNA; (9) use of a (I) or (1) for the treatment of steroidal hormone dependent illnesses; (10) use of (I), (1), or (6) for the identification of the effectiveness of a (1); (11) a test system for the detection of the effect of (1) in a cell where a reporter gene is expressed in a cell, which if it contains no or only a little of a nuclear receptor, is transfected additionally with a vector, which contains the DNA of the nuclear receptor, the cell in the presence or absence of test substances is cultivated and the change of the expression of the reporter gene is measured; and (12) process for the supply of a pharmaceutical means, comprising that substances are brought into contact with a test system of (11), the effect of the substances on the test system compared with controls measured, a substance which shows a modulation of the activity of the polypeptide identified and mixed with usual formulation materials.
DK02015042T 2001-07-23 2002-07-05 Co-activators of nuclear receptors DK1288227T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10135787A DE10135787A1 (en) 2001-07-23 2001-07-23 New nucleic acid for producing a recombinant polypeptide, for use as a probe, or for the treatment of steroidal hormone dependent illnesses

Publications (1)

Publication Number Publication Date
DK1288227T3 true DK1288227T3 (en) 2006-07-24

Family

ID=7692769

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02015042T DK1288227T3 (en) 2001-07-23 2002-07-05 Co-activators of nuclear receptors

Country Status (8)

Country Link
EP (1) EP1288227B1 (en)
JP (1) JP2003144179A (en)
AT (1) ATE321780T1 (en)
DE (2) DE10135787A1 (en)
DK (1) DK1288227T3 (en)
ES (1) ES2261557T3 (en)
NO (1) NO20023483L (en)
PT (1) PT1288227E (en)

Also Published As

Publication number Publication date
ES2261557T3 (en) 2006-11-16
PT1288227E (en) 2006-07-31
NO20023483D0 (en) 2002-07-22
JP2003144179A (en) 2003-05-20
DE50206196D1 (en) 2006-05-18
ATE321780T1 (en) 2006-04-15
NO20023483L (en) 2003-01-24
EP1288227A1 (en) 2003-03-05
EP1288227B1 (en) 2006-03-29
DE10135787A1 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
Cordle et al. Pancreatic β-cell-type-specific transcription of the insulin gene is mediated by basic helix-loop-helix DNA-binding proteins
Yalamanchili et al. Cleavage of transcriptional activator Oct-1 by poliovirus encoded protease 3Cpro
Gentz et al. Bioassay for trans-activation using purified human immunodeficiency virus tat-encoded protein: trans-activation requires mRNA synthesis.
Wower et al. Binding and cross‐linking of tmRNA to ribosomal protein S1, on and off the Escherichia coli ribosome
Joukov et al. Proteolytic processing regulates receptor specificity and activity of VEGF‐C
Gilman The c-fos serum response element responds to protein kinase C-dependent and-independent signals but not to cyclic AMP.
JP4086315B2 (en) Regulatory genes and uses thereof
Gayle et al. Cloning of a Putative Ligand for the T1/ST2 Receptor (∗)
Hershberger et al. Cell-type-specific expression of alternatively spliced human fibronectin IIICS mRNAs
DE69840361D1 (en) NEW BONE MINERALIZATION PROTEINS, DNA, VECTORS, EXPRESSION SYSTEMS
IL138593A (en) Glial factor receptor ??3 (gfr??3) polypeptide, nucleic acid encoding the same, process for preparation thereof, vectors, host cells, antibodies, chimeric molecules and use of such gfr??3
Grujicic et al. Functional characterization of the human SOX3 promoter: identification of transcription factors implicated in basal promoter activity
McQueen et al. Skeletal muscle differentiation drives a dramatic downregulation of RNA polymerase III activity and differential expression of Polr3g isoforms
WO1996040040A3 (en) Thrombin receptor homolog
Lee et al. Enzymatic activation of autotaxin by divalent cations without EF-hand loop region involvement
Gao et al. Functional importance of the cyclic AMP response element-like decamer motif in the CD8 alpha promoter.
DK1288227T3 (en) Co-activators of nuclear receptors
Hirai et al. Stimulation of ubiquitin–proteasome pathway through the expression of amidohydrolase for N‐terminal asparagine (Ntan1) in cultured rat hippocampal neurons exposed to static magnetism
US7226744B2 (en) Assays for TERT promoter modulatory agents using a telomerase structural RNA component
CA2270431A1 (en) Method for the detection of compounds that modulate the effects of the obese (ob) protein
KR100553154B1 (en) Mammalian expression vector for nucleocapsid protein of HIV and preparation method thereof
JP2005507651A5 (en)
WO2003057827A3 (en) Insulin-responsive dna binding protein-1 and methods to regulate insulin-responsive genes
MX9701596A (en) A human map kinase homolog.
CA2418848A1 (en) Cng2b: a novel human cyclic nucleotide-gated ion channel